Efficacy of early administration of levosimendan in emergency department in patients with acute heart failure: A randomized pilot clinical trial;Eficacia de la administración precoz de levosimendán en urgencias en pacientes con insuficiencia cardiaca aguda: Un ensayo clínico piloto aleatorizado

Emergencias

Volumn 24, Issue 4, 2012, Pages 268-276

  Llorens, Pere ^a   Miró, Òscar ^b   Román, Francisco ^a   Zapater, Pedro ^a   Carbajosa Dalmau, José ^a   Llanos, Lucía ^a  

^a HOSPITAL GENERAL UNIVERSITARIO DE ALICANTE   (Spain)

^b HOSPITAL CLÍNIC   (Spain)

Author keywords

Acute heart failure; Emergency Department; Levosimendan

Indexed keywords

EID: 84865525585     PISSN: 11376821     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (33)

1. Llorens P, Miró O, Martín Sánchez FJ, Herrero Puente P, Jacob Rodríguez J, Gil V, et al. Guidelines for emergency management of acute heart failure: consensus of the Acute Heart Failure Working Group of the Spanish Society of Emergency Medicine (ICA-SEMES) in 2011. Emergencias. 2011;23:119-39.
2. Dickstein K, Cohen-Solal A, Filippatos G, McMurray J, Ponikowski P, Poole-Wilson PA, et al. ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2008. Eur Heart J. 2008;29:2388-442.
3. Thackray S, Easthaugh J, Freemantle N, Cleland JG. The effectiveness and relative effectiveness of intravenous inotropic drugs acting through the adrenergic pathway in patients with heart failure-a meta-regression analysis. Eur J Heart Fail. 2002;4:515-29.
4. Parissis JT, Filippatos G, Farmakis D, Adamopoulos S, Paraskevaidis I, Kremastinos D. Levosimendan for the treatment of acute heart failure syndromes. Expert Opin Pharmacother. 2005;6:2741-51.
5. Antila S, Sundberg S, Lehtonen LA. Clinical pharmacology of levosimendan. Clin Pharmacokinet. 2007;46:535-52.
6. De Luca L, Colucci WS, Nieminen MS, Massie BM, Gheorghiade M. Evidence-based use of levosimendan in different clinical setting. Eur Heart J. 2006;27:1908-20.
7. Parissis JT, Panou F, Farmakis D, Adamopoulos S, Filippatos G, Paraskevaidis I, et al. Effects of levosimendan on markets of left ventricular diastolic function and neurohormonal activation in patients with advanced heart failure. Am J Cardiol. 2005;96:423-6.
8. Follath F, Cleland JG, Just H, Papp JG, Scholz H, Peuhkurinen K, et al. Steering Committee and Investigators of the Levosimendan Infusion versus Dobutamine (LIDO) Study. Efficacy and safety of intravenous levosimendan compared with dobutamine in severe low-output heart failure (the LIDO study): a randomised double-blind trial. Lancet. 2002;360:196-202.
9. Moiseyev VS, Põder P, Andrejevs N, Ruda MY, Golikov AP, Lazebnik LB, et al. RUSSLAN Study Investigators. Safety and efficacy of a novel calcium sensitizer, levosimendan, in patients with left ventricular failure due to an acute myocardial infarction. A randomized, placebocontrolled, double-blind study (RUSSLAN). Eur Heart J. 2002;23:1422-32.
10. Coletta AP, Cleland JGF, Freemantle N, Clark AL. Clinical trials update from the European Society of Cardiology Heart Failure meeting: SHAPE, BRING-UP 2 VAS, COLA II, FOSIDIAL, BETACAR, CASINO and meta-analysis of cardiac resynchronisation therapy. Eur J Heart Fail. 2004;6:673-6.
11. Follath F, Franco F, Cardoso JS. European experience on the practical use of levosimendan in patients with acute heart failure syndromes. Am J Cardiol. 2005;96:80-5.
12. Nieminen MS, Bohm M, Cowie MR, Drexler H, Filippatos GS, Jondeau G, et al. Executive summary of the guidelines on the diagnosis and treatment of acute heart failure. Eur Heart J. 2005;26:384-416.
13. Llorens-Soriano P, Carbajosa-Dalmau J, Fernández-Cañadas J, Murcia-Zaragoza J, Climent-Payá V, Laghzaoui F, et al. Clinical Experience With Levosimendan in the Emergency Department of a Tertiary Care Hospital. Rev Esp Cardiol. 2007;60:878-982.
14. Framingham McKee PA, Castelli WP, McNamara PM, Kannel WB. The natural history of congestive heart failure: the Framingham study. N Engl J Med. 1971;285:1441-6.
15. Swedberg K, Cleland J, Dargie H, Drexler H, Follath F, Komajda M, et al. Guidelines for the diagnosis and treatment of chronic heart failure: executive summary (update 2005): The Task Force for the Diagnosis and Treatment of Chronic Heart Failure of the European Society of Cardiology. Eur Heart J. 2005;26:1115-40.
16. O'Connor CM, Starling RC, Hernández AF, Armstrong PW, Dickstein K, Hasselblad V, et al. Effect of nesiretide in patients with descomensated heart failure. N Engl J Med. 2011;365:32-43.
17. Slawsky MT, Colucci WS, Gottlieb SS, Greenberg BH, Haeusslein E, Hare J, et al. Acute hemodynamic and clinical effects of levosimendan in patients with severe heart failure. Study Investigators. Circulation. 2000;102:2222-7.
18. Cleland JGF, Freemantle N, Coletta AP, Clark AL. Clinical trials update from the American Heart Association: REPAIR-AMI, ASTAMI, JELIS, MEGA, REVIVE-II, SURVIVE, and PROACTIVE. Eur J Heart Fail. 2006;8:105-10.
19. Lilleberg J, Laine M, Palkama T, Kivikko, Pohjanjousi P, Kupari M. Duration of the haemodynamic action of a 24-h infusion of levosimendan in patients with congestive heart failure. Eur J Heart Fail. 2007;9:75-82.
20. Goebel JA, Van Bakel AB. Rational use of diuretics in acute decompensated heart failure. Current Heart Failure Reports. 2008;5:153-62.
21. Felker GM. Diuretic Management in Heart Failure. Congestive Heart Fail. 2010;16(supl):S68-S72.
22. Branzi G, Malfatto G, Villani A, Ciambellotti F, Revera M, Giglio A, et al. Acute effects of levosimendan on mitral regurgitation and diastolic function in patients with advanced chronic heart failure. J Cardiovasc Med (Hagerstown). 2010;11:662-8.
23. Jacob J, Llorens P, Martín-Sánchez FJ, Herrero P, Álvarez A, Pérez-Durá MJ, et al. Prognostic value of emergency department testing for Nterminal fragment of brain natriuretic peptide in patients with acute heart failure. The PICASU-1 study. Emergencias. 2011;23:183-92.
24. Miró O, Jacob J, Martín-Sánchez FJ, Herrero P, Pavón J, Pérez-Dura MJ, et al. Prognostic implications on the possibility to urgent testing for N-terminal fragment of brain natriuretic peptide in emergency department in patients with acute heart failure: the PICASU-2 study. Emergencias. 2011;23:437-46.
25. Miró Ò, Llorens P, Martín-Sánchez FJ, Herrero P, Pavón J, Pérez-Durá MJ, et al. Short-term prognostic factors in elderly patients seen in emergency department for acute heart failure. Rev Esp Cardiol. 2009;62:757-64.
26. Delaney A, Bardford C, McCaffrey J, Bagshaw SM, Lee R. Levosimendan for the treatment of acute severe heart failure: A meta-analysis of randomised controlled trials. Int J Cardiol. 2010;138:281-9.
27. Mebazaa A, Gheorghiade M, Piña I, Harjola VP, Hollenberg S, Follath F, et al. Practical recommendations for prehospital and early in-hospital management of patients presenting with acute heart failure syndromes. Crit Care Med. 2008;36(supl):S129-39.
28. Mebazaa A, Nieminen MS, Packer M, Cohen-Solal A, Kleber FX, Pocock SJ, et al. SURVIVE Investigators. Levosimendan vs dobutamine for patients with acute decompensated heart failure: the SURVIVE Randomized Trial. JAMA. 2007;297:1883-91.
29. Parissis JT, Papadopoulos C, Nikolaou M, Bistola V, Farmakis D, Paraskevaidis I, et al. Effects of Levosimendan on quality of life and emotional stress in advanced heart failure patients. Cardiovasc Drug Ther. 2007;21:263-8.
30. Miró Ò, Llorens P, Martín-Sánchez FJ, Herrero P, Jacob J, Pérez-Durá MJ, et al. Predicting the risk of reattendance for acute heart failure patients discharged from Spanish Emergency Department observation units. Eur J Emerg Med. 2010;17:197-202.
31. Teerlink JR, Metra M, Zacà V, Sabbah HN, Cotter G, Gheorghiade M, et al. Agents with inotropic properties for the management of acute heart failure syndromes. Tradicional agents and beyond. Heart Fail Rev. 2009;14:243-53.
32. Parissis JT, Rafouli-Stergiou P, Paraskevaidis I, Mebazaa A. Levosimendan: from basic science to clinical practice. Heart Fail Rev. 2009;14:265-75.
33. Holley AD, Ziegenfuss M. Levosimendan: A new option in acute cardiac failure. Emerg Med Australas. 2006;18:505-9.